共 50 条
- [1] Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+Year Results of a 5-Year, Open-Label Extension Study [J]. HEADACHE, 2019, 59 : 25 - 25
- [5] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 17 - 17
- [8] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study [J]. HEADACHE, 2021, 61 : 117 - 118
- [9] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine [J]. HEADACHE, 2021, 61 (04): : 653 - 661
- [10] Long-term safety and tolerability of erenumab: Three-plus year results from an ongoing open-label extension study in episodic migraine [J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19